Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

The effect of treatment on patient-reported distress after breast cancer diagnosis.

Fayanju OM, Yenokyan K, Ren Y, Goldstein BA, Stashko I, Power S, Thornton MJ, Marcom PK, Hwang ES.

Cancer. 2019 May 23. doi: 10.1002/cncr.32174. [Epub ahead of print]

PMID:
31120575
2.

Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool.

Kikuchi R, Broadwater G, Shelby R, Robertson J, Zullig LL, Maloney B, Meyer C, Mungal D, Marcom PK, Kanesvaran R, White H, Kimmick G.

J Geriatr Oncol. 2019 Apr 17. pii: S1879-4068(18)30404-1. doi: 10.1016/j.jgo.2019.04.010. [Epub ahead of print]

PMID:
31005647
3.

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).

Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM.

Breast Cancer Res Treat. 2019 Jul;176(2):303-310. doi: 10.1007/s10549-019-05238-4. Epub 2019 Apr 19.

PMID:
31004299
4.

Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.

Dorfman CS, Arthur SS, Kimmick GG, Westbrook KW, Marcom PK, Corbett C, Edmond SN, Shelby RA.

Menopause. 2019 Apr 15. doi: 10.1097/GME.0000000000001337. [Epub ahead of print]

PMID:
30994574
5.

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP.

J Clin Oncol. 2019 Apr 2:JCO1900066. doi: 10.1200/JCO.19.00066. [Epub ahead of print]

PMID:
30939096
6.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2019 Feb;17(2):118-126. doi: 10.6004/jnccn.2019.0009.

PMID:
30787125
7.

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM.

Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047.

PMID:
30753274
8.

Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer.

Mazurowski MA, Saha A, Harowicz MR, Cain EH, Marks JR, Marcom PK.

J Magn Reson Imaging. 2019 Jun;49(7):e231-e240. doi: 10.1002/jmri.26648. Epub 2019 Jan 22.

PMID:
30672045
9.

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop T, Kim S, Rogatko A, Lubkov V, Snyder JC, Osada T, Hobeika AC, Morse MA, Lyerly HK, Hartman ZC.

Clin Cancer Res. 2019 May 1;25(9):2725-2736. doi: 10.1158/1078-0432.CCR-18-3102. Epub 2019 Jan 11.

PMID:
30635338
10.

Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.

Sitlinger A, Shelby RA, Van Denburg AN, White H, Edmond SN, Marcom PK, Bosworth HB, Keefe FJ, Kimmick GG.

J Geriatr Oncol. 2019 Mar;10(2):317-321. doi: 10.1016/j.jgo.2018.11.008. Epub 2018 Dec 13.

PMID:
30553719
11.

Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.

Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA.

Breast Cancer Res Treat. 2019 Jan;173(2):455-463. doi: 10.1007/s10549-018-4990-9. Epub 2018 Oct 16.

PMID:
30328048
12.

Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.

Saha A, Harowicz MR, Cain EH, Hall AH, Hwang ES, Marks JR, Marcom PK, Mazurowski MA.

Breast Cancer Res Treat. 2018 Nov;172(1):123-132. doi: 10.1007/s10549-018-4879-7. Epub 2018 Jul 10.

PMID:
29992418
13.

Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.

Force J, Howie LJ, Abbott SE, Bentley R, Marcom PK, Kimmick G, Westbrook K, Sammons SL, Parks M, Topping DL, Emerson R, Broadwater G, Hyslop T, Blackwell KL, Nair SK.

Clin Breast Cancer. 2018 Oct;18(5):410-417. doi: 10.1016/j.clbc.2018.02.010. Epub 2018 Feb 24.

PMID:
29615305
14.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012.

PMID:
29523670
15.

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC.

Clin Breast Cancer. 2018 Aug;18(4):289-297. doi: 10.1016/j.clbc.2017.10.014. Epub 2017 Oct 28.

PMID:
29153866
16.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.

Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

17.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Apr;15(4):433-451.

PMID:
28404755
18.

Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Harowicz MR, Saha A, Grimm LJ, Marcom PK, Marks JR, Hwang ES, Mazurowski MA.

J Magn Reson Imaging. 2017 Nov;46(5):1332-1340. doi: 10.1002/jmri.25655. Epub 2017 Feb 9.

19.

Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.

Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA.

Breast Cancer Res Treat. 2017 Feb;162(1):1-10. doi: 10.1007/s10549-016-4093-4. Epub 2017 Jan 7.

20.

Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.

Nelson ER, Li S, Kennedy M, Payne S, Kilibarda K, Groth J, Bowie M, Parilla-Castellar E, de Ridder G, Marcom PK, Lyes M, Peterson BL, Cook M, Pizzo SV, McDonnell DP, Bachelder RE.

Oncotarget. 2016 Dec 20;7(51):84030-84042. doi: 10.18632/oncotarget.12767.

21.

Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.

Kamal A, Zhang T, Power S, Marcom PK.

J Natl Compr Canc Netw. 2016 Aug;14(8):993-8.

PMID:
27496115
22.

Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.

Buchanan AH, Voils CI, Schildkraut JM, Fine C, Horick NK, Marcom PK, Wiggins K, Skinner CS.

J Genet Couns. 2017 Feb;26(1):79-92. doi: 10.1007/s10897-016-9981-6. Epub 2016 Jun 6.

23.

Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Mar;14(3):324-54.

PMID:
26957618
24.

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S.

J Natl Compr Canc Netw. 2016 Feb;14(2):153-62.

PMID:
26850485
25.

NCCN Guidelines Insights Breast Cancer, Version 1.2016.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.

PMID:
26656517
26.

CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.

Sutton LM, Geradts J, Hamilton EP, Havlin KA, Kimmick GG, Marcom PK, Spector NL, Watson M, Rabin DU, Bruno TO, Noe A, Miller S, Subramaniam C, Layton S, Grichnik K.

J Natl Compr Canc Netw. 2015 Aug;13(8):1005-11.

PMID:
26285246
27.

Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms.

Mazurowski MA, Grimm LJ, Zhang J, Marcom PK, Yoon SC, Kim C, Ghate SV, Johnson KS.

Eur J Radiol. 2015 Nov;84(11):2117-22. doi: 10.1016/j.ejrad.2015.07.012. Epub 2015 Jul 18.

PMID:
26210095
28.

Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.

Kimmick G, Edmond SN, Bosworth HB, Peppercorn J, Marcom PK, Blackwell K, Keefe FJ, Shelby RA.

Breast. 2015 Oct;24(5):630-6. doi: 10.1016/j.breast.2015.06.010. Epub 2015 Jul 16.

29.

Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.

Li S, Payne S, Wang F, Claus P, Su Z, Groth J, Geradts J, de Ridder G, Alvarez R, Marcom PK, Pizzo SV, Bachelder RE.

Breast Cancer Res. 2015 Jul 4;17:91. doi: 10.1186/s13058-015-0590-3.

30.

Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.

Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM.

Breast Cancer Res Treat. 2015 Jul;152(2):347-56. doi: 10.1007/s10549-015-3476-2. Epub 2015 Jun 25.

31.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

32.

Breast Cancer Version 2.2015.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2015 Apr;13(4):448-75.

PMID:
25870381
33.

Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance.

Buchanan AH, Datta SK, Skinner CS, Hollowell GP, Beresford HF, Freeland T, Rogers B, Boling J, Marcom PK, Adams MB.

J Genet Couns. 2015 Dec;24(6):961-70. doi: 10.1007/s10897-015-9836-6. Epub 2015 Apr 3.

34.

Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer.

Aziz H, Marcom PK, Hwang ES.

Ann Surg Oncol. 2015 May;22(5):1404-5. doi: 10.1245/s10434-015-4503-6. Epub 2015 Mar 17. No abstract available.

PMID:
25777094
35.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.

N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. Erratum in: N Engl J Med. 2015 Nov 12;373(20):1989.

36.

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2015 Mar 1;21(5):1098-105. doi: 10.1158/1078-0432.CCR-14-1948. Epub 2014 Dec 18. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3356-7.

37.

Can breast cancer molecular subtype help to select patients for preoperative MR imaging?

Grimm LJ, Johnson KS, Marcom PK, Baker JA, Soo MS.

Radiology. 2015 Feb;274(2):352-8. doi: 10.1148/radiol.14140594. Epub 2014 Oct 15.

PMID:
25325325
38.

Patient experience and attitudes toward addressing the cost of breast cancer care.

Irwin B, Kimmick G, Altomare I, Marcom PK, Houck K, Zafar SY, Peppercorn J.

Oncologist. 2014 Nov;19(11):1135-40. doi: 10.1634/theoncologist.2014-0117. Epub 2014 Oct 1.

39.

Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38.

PMID:
25190698
40.

The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.

Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG.

J Biopharm Stat. 2015;25(1):66-88. doi: 10.1080/10543406.2014.919933.

41.

Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.

Shelby RA, Edmond SN, Wren AA, Keefe FJ, Peppercorn JM, Marcom PK, Blackwell KL, Kimmick GG.

Support Care Cancer. 2014 Oct;22(10):2851-9. doi: 10.1007/s00520-014-2269-1. Epub 2014 May 13.

PMID:
24821365
42.

Breast cancer version 3.2014.

Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network Breast Cancer Panel.

J Natl Compr Canc Netw. 2014 Apr;12(4):542-90.

PMID:
24717572
43.

Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute.

Kamal AH, Power S, Broadwater G, Holland AR, Marcom PK.

J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S21-4.

44.

Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment.

Edmond SN, Shelby RA, Kimmick GG, Marcom PK, Peppercorn JM, Keefe FJ.

J Psychosoc Oncol. 2013;31(6):698-711. doi: 10.1080/07347332.2013.835023.

PMID:
24175903
45.

Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.

Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, Broadwater G, Blackwell K.

Clin Breast Cancer. 2013 Dec;13(6):416-20. doi: 10.1016/j.clbc.2013.08.003. Epub 2013 Oct 4.

PMID:
24099649
46.

Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.

Peppercorn J, Hamilton E, Marcom PK, Beskow L, Lyman GH.

Cancer. 2013 Oct 15;119(20):3703-9. doi: 10.1002/cncr.28263. Epub 2013 Jul 24.

47.

Breast cancer, version 3.2013: featured updates to the NCCN guidelines.

Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Jul;11(7):753-60; quiz 761.

48.

Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.

Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, Povsic TJ, Peppercorn J, Marcom PK, Blackwell KL, Kimmick G, Turkington TG, Dewhirst MW.

Cancer Prev Res (Phila). 2013 Sep;6(9):925-37. doi: 10.1158/1940-6207.CAPR-12-0416. Epub 2013 Jul 10.

49.

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.

Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU.

Breast Cancer Res. 2012 Oct 1;14(5):R129. doi: 10.1186/bcr3324.

50.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):821-9.

Supplemental Content

Loading ...
Support Center